# Senan Ebrahim

> Senan Ebrahim is the founder and CEO of Delfina, a San Francisco digital health company using AI and data science to improve pregnancy care and close gaps in maternal health. A physician-scientist with an MD and a PhD in computational neuroscience from Harvard, he founded Delfina after witnessing a preventable stillbirth during medical training. He earlier founded Hikma Health, a nonprofit building free health-data tools for refugee and low-income patients. Delfina raised a $17M Series A in early 2025 led by U.S. Venture Partners.

- **Role:** Founder & CEO at Delfina
- **Organizations:** Delfina, Hikma Health
- **From:** San Jose, California, USA
- **Nationality:** American
- **Education:** AB in Neurobiology, Harvard University, MD, Harvard / MIT (joint MD-PhD program), PhD in Computational Neuroscience (machine learning to predict seizures), Harvard University
- **Known for:** Founded Delfina, an AI-powered maternal health platform, Founded Hikma Health, a nonprofit serving refugees and low-income patients, Elected president of the Harvard College student body

## Career timeline

- **2013** — Awarded the Paul & Daisy Soros Fellowship for New Americans
- **2010s** — Founded Hikma Health, a nonprofit health-data platform for refugee and low-income patients
- **2020** — Founded Delfina to build AI-powered pregnancy care
- **2022** — Delfina raised a $5.3M seed round for its AI pregnancy platform
- **2023** — Delfina partnered with Blue Cross and Blue Shield of Texas on maternal-infant health
- **2025** — Delfina closed a $17M Series A led by U.S. Venture Partners; won MedTech Breakthrough 'Best Maternal Health Platform of 2025'

## Achievements

- Founded Delfina, an AI-powered maternal health platform
- Founded Hikma Health, a nonprofit serving refugees and low-income patients
- Elected president of the Harvard College student body
- Paul & Daisy Soros Fellow (2013)
- Earned an MD and a PhD in computational neuroscience from Harvard/MIT
- Led Delfina to a $17M Series A with backers including U.S. Venture Partners, Mayo Clinic, ARTIS Ventures and Metrodora Ventures
- Delfina named MedTech Breakthrough 'Best Maternal Health Platform of 2025'

## Latest updates

- **2025-01** — Delfina closed a $17M Series A led by U.S. Venture Partners with Mayo Clinic, ARTIS Ventures, Tokio Marine Future Fund and Metrodora Ventures participating.
- **2025-01** — Delfina named 'Best Maternal Health Platform of 2025' by MedTech Breakthrough.

## Links

- Website: https://delfina.com
- LinkedIn: http://www.linkedin.com/in/senane
- Twitter/X: https://twitter.com/DelfinaCare
- Facebook: https://www.facebook.com/DelfinaCareAI/

---

Profile page: https://yespress.io/senan-ebrahim
Published by YesPress — https://yespress.io
Last updated: 2026-07-29